After more than a decade and a half in development, the FDA’s Cardiovascular and Renal Drugs Advisory Committee today voted 8-3 against approval of Cytokinetics’ heart failure drug.
Adcomm members said the drug’s potential benefits did not seem to outweigh its risks, with panel members raising concerns about the drug’s safety and its limited efficacy....
https://endpts."dot"/fda-adcomm-votes-8-3-against-cytokinetics-potential-heart-failure-drug/?utm_medium=email&utm_campaign=223%20-%20Breaking%20FDA%20adcomm%20votes%20against%20potential%20heart%20drug%20Eli%20Lilly%20looks%20ahead%20to%20near-term%20wins%20Basic&utm_content=223%20-%20Breaking%20FDA%20adcomm%20votes%20against%20potential%20heart%20drug%20Eli%20Lilly%20looks%20ahead%20to%20near-term%20wins%20Basic+CID_0988e104bdf2bad05f0222424327c210&utm_source=ENDPOINTS%20emails&utm_term=FDA%20adcomm%20votes%208-3%20against%20Cytokinetics%20potential%20heart%20failure%20drug
Ann: Rexlemestrocel-L Improves LVEF, Preceding Reduction in MACE, page-295
-
- There are more pages in this discussion • 5 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.49 |
Change
0.140(10.4%) |
Mkt cap ! $1.701B | |||
| Open | High | Low | Value | Volume |
| $1.37 | $1.54 | $1.37 | $23.10M | 15.82M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 3 | 24758 | $1.49 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.49 | 73626 | 3 |
View Market Depth
| Last trade - 16.10pm 04/10/2024 (20 minute delay) ? |
| MSB (ASX) Chart |